MRI Safe Cardiac Resynchronization Therapy Device Market

MRI safe cardiac resynchronization therapy device treats the patients with moderate as well as severe symptoms of heart failure and the effectiveness of the therapy is equal in both men and women. The MRI safe cardiac resynchronization therapy devices are implanted in the body. The device is a pocket sized pacemaker, and is implanted just below the collarbone. The leads from the device, monitors the heart rate to detect the heart rate abnormalities and transmits small pulses to resynchronize the heart?s ventricles. The therapy device improves the heart rhythm and the symptoms associated with arrhythmia.
MRI Safe Cardiac Resynchronization Therapy Device Market contains market size and forecasts of MRI Safe Cardiac Resynchronization Therapy Device in global, including the following market information:
Global MRI Safe Cardiac Resynchronization Therapy Device Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global MRI Safe Cardiac Resynchronization Therapy Device Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five MRI Safe Cardiac Resynchronization Therapy Device companies in 2021 (%)
The global MRI Safe Cardiac Resynchronization Therapy Device market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pacemaker Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of MRI Safe Cardiac Resynchronization Therapy Device include Abbott, Medtronic, Boston Scientific, Cook Group, Philips, LivaNova, MicroPort Scientific, BIOTRONIK and Medico, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the MRI Safe Cardiac Resynchronization Therapy Device manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global MRI Safe Cardiac Resynchronization Therapy Device Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MRI Safe Cardiac Resynchronization Therapy Device Market Segment Percentages, by Type, 2021 (%)
Pacemaker
Defibrillator
Global MRI Safe Cardiac Resynchronization Therapy Device Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MRI Safe Cardiac Resynchronization Therapy Device Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Home Care Setting
Global MRI Safe Cardiac Resynchronization Therapy Device Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MRI Safe Cardiac Resynchronization Therapy Device Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies MRI Safe Cardiac Resynchronization Therapy Device revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies MRI Safe Cardiac Resynchronization Therapy Device revenues share in global market, 2021 (%)
Key companies MRI Safe Cardiac Resynchronization Therapy Device sales in global market, 2017-2022 (Estimated), (K Units)
Key companies MRI Safe Cardiac Resynchronization Therapy Device sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott
Medtronic
Boston Scientific
Cook Group
Philips
LivaNova
MicroPort Scientific
BIOTRONIK
Medico
Qinming Medical
IMZ
Cardioelectronica
Pacetronix